Your session is about to expire
← Back to Search
Behavioral Intervention
Psychological Mobile App for Patients With AML
N/A
Waitlist Available
Led By Areej El-Jawahri, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is comparing two mobile apps for patients with acute myeloid leukemia. One app, DREAMLAND, provides psychological support to help reduce anxiety and depression. The other app, CERENA, offers tips on staying physically healthy. The goal is to see which app better improves the patients' quality of life.
Eligible Conditions
- Acute Myeloid Leukemia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Anxiety Symptoms
Depression Symptoms
Post-Traumatic Stress Disorder (PTSD) Symptoms
+2 moreOther study objectives
Coping
Health care utilization
Self-efficacy
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: DREAMLANDExperimental Treatment1 Intervention
Participants will be recruited from 5 sites and randomized in 1:1 fashion, stratified by study site, to DREAMLAND versus CERENA.
* Participants will use DREAMLAND and during hospitalization for treatment of AML to learn how to cope most effectively with the diagnosis of AML using an iPad provided by the study team or participant's own iPad.
* Questionnaires (in-person, over the computer or telephone, or by mail) at predetermined days per protocol days.
Group II: CERENAActive Control1 Intervention
Participants will be recruited from 5 sites and randomized in 1:1 fashion, stratified by study site, to DREAMLAND versus CERENA.
* Participants will use the mobile app CERENA during hospitalization for treatment of AML to learn how to best care for themselves using an iPad provided by the study team or participant's own iPad.
* Questionnaires (in-person, over the computer or telephone, or by mail) at predetermined days per protocol days.
Find a Location
Who is running the clinical trial?
Blue Note TherapeuticsIndustry Sponsor
6 Previous Clinical Trials
770 Total Patients Enrolled
Massachusetts General HospitalLead Sponsor
3,023 Previous Clinical Trials
13,317,938 Total Patients Enrolled
Areej El-Jawahri, MDPrincipal InvestigatorMassachusetts General Hospital
20 Previous Clinical Trials
5,428 Total Patients Enrolled